Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

The case centers on claims Vistagen misled the market about fasedienol’s clinical prospects.

Overview

Plaintiff firms including the Schall Law Firm and DJS Law Group are recruiting VTGN investors to seek lead‑plaintiff status before the March 16, 2026 deadline, and the class has not yet been certified.
The alleged class period covers purchases of Vistagen securities from April 1, 2024 through December 16, 2025.
The lawsuit asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5.
Complaints allege Vistagen misrepresented PALISADE‑2 findings and conveyed an overstated likelihood of Phase 3 success while downplaying clinical risk.
On December 17, 2025, Vistagen reported PALISADE‑3 failed its primary SUDS endpoint, and the stock fell more than 81% to open at $0.88.